This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
It was expected that the Affordable Care Act would lead to many employers dropping health benefits, but that did not happen, a new report from the Employee Benefit Research Institute found.
A former WHO epidemiologist is applying lessons learned during the Ebola epidemic to her work leading a company at the forefront of women’s health: the reproductive microbiome.
For documents published in 2014 this number was just six; in 2024 it was 157 ( Figure 2 ). 2014-2024 (Credit: Elsevier BV – Scopus) Figure 2 : Documents by year. 2014-2024 (Credit: Elsevier BV – Scopus) Regionally, the US is dominating rare disease research. 1 Figure 1 : Documents by year.
He joined Takeda as CEO in April 2014. Christophe Weber is set to retire as Chief Executive Officer (CEO) of Takeda in June 2026 after 12 years.Julie Kim, president of Takedas US Business Unit has been appointed as Webers successor. Weber is the companys current President, CEO and representative director.
He leads the Program on Regulation, Therapeutics, and Law at Brigham and Women’s Hospital in Boston. Data were mainly accessible for smaller firms, products in some therapeutic regions, orphan drugs, first-in-class drugs, therapeutic agents that received accelerated approval, and products between 2014 and 2018.
The panelists referred to other documents that are useful for CCS development: the 2014 Pharmaceutical Healthcare Sciences Society (PHSS) Technical Monograph No 20 Bio-Contamination 2 as well as the Parenteral Drug Association (PDA) Technical Report 90: Contamination Control Strategy Development, 3 published in February 2023.
While that sounds encouraging, most cancer drugs launched between 2009 and 2014 cost more than USD 100,000 annually. This leads to a question; “where does it end?” COVID-19 has not impacted the number of launches in the oncology space, as 2020 and 2021 have seen similar rates of drug launches as in 2019.
The UK’s share of global research and development ( R&D ) investment has fallen by a fifth since 2014, according to recent data analysis by the Institute for Public Policy Research (IPPR). According to IPPR’s research, the UK would need to invest an extra £62 billion in 2022 to overtake Israel, the leading R&D spender.
. “If I had had that information at the beginning, I could have avoided the treatments I received that were never going to work,” added Stephen who was diagnosed with metastatic breast cancer in March 2014. Why not lead?” Let’s lead by doing things – by making decisions to lead.”
AbbVie has leading positions in haematology oncology treatments with BTK and BCL-2 inhibitors as foundational therapies in CLL and other blood cancers. While at Roche, she also held various positions, such as Global Medical Lead in Oncology in Switzerland and Medical Manager in Brazil.
“Obesity is a leading cause of preventable disease and death among U.S. ” According to a 2014 study by the Intramural Research Program — a subsidiary of the National Institutes of Health—extreme obesity may shorten life expectancy by up to 14 years. at the National Institutes of Health. ’s U.S.ident for P.R.B.’s
There is disagreement whether obesity is really considered a disease or a behavioral risk factor, similar to smoking, alcohol, and substance abuse that may lead to disease. Some of the environmental conditions that lead to obesity are physical activity, alcohol consumption, socioeconomic status, parent feeding behavior, and diet.
The Cedars-Sinai Board of Governors Regenerative Medicine Institute and the Smidt Heart Institute will lead the project. The advanced facility will be based on the Regenerative Medicine Clinic established at Cedars-Sinai in 2014, developing clinical trials for neurological, cardiovascular, musculoskeletal and autoimmune diseases.
Pfizer licensed BEQVEZ from Spark Therapeutics in December 2014. BEQVEZ is currently being reviewed by the European Medicines Agency (EMA), Pfizer confirmed. Article: The evolution of AAVs in cell and gene therapy The post Novel haemophilia B gene therapy approved appeared first on European Pharmaceutical Review.
One of a group of muscular dystrophies, DMD leads to a gradual loss of muscle function, often with children having to use a wheelchair by their early adolescence. Translarna has had European approval for usage since 2014 and has also been available under terms similar to the MAA to DMD patients in Scotland since 2021.
First approved in 2014, the drug is also used for a range of indications across ovarian, breast, fallopian tube, peritoneal and pancreatic cancers, and remains one of AZ’s fastest growing oncology therapies, with sales rising 18% to almost $1.3 billion in the first half of this year. .
A just-published report from the Medicines Manufacturing Industry Partnership (MMIP) – set up by the UK government and biopharma industry in 2014 to drive growth in the category – says the sector has the potential to be a driver for the UK economy in the next decade.
There are more than 200 lung disorders that can lead to pulmonary fibrosis. First approved back in 2014, it is still growing strongly, with its 2021 sales of €2.5 Boehringer is a well-established presence in the IPF treatment market with Ofev (nintedanib), one of the German drugmaker’s top-selling drugs.
It’s worth recalling that Dekkers first announced his intention to step down in 2014, with Baumann elevated to the role of chef strategy and portfolio officer shortly afterwards to prepare him to take on the top job two years later.
In the next 12 months, the organisation will conduct the work leading up to investigational new drug (IND) submissions for new gene therapies. The AMP was launched in 2014 as a partnership between the FDA , the National Institutes for Health, and several public and private organisations.
According to GlobalData’s Clinical Trials Database, gene therapy trials represent a 0.91% share of all planned trials in 2023, up from just 0.25% in 2014. GlobalData, the parent company of Pharmaceutical Technology, outlines a rise in gene therapy trials in 2023, in line with the growing market Fáber describes.
In 2014, the first stem-cell therapy was recommended for approval in EU by the European Medicines Agency (EMA). The stem cell therapy offered these outcomes because “reduced inflammation resulting from the activation of MPCs may decrease plaque instability, which is what leads to heart attacks and strokes.” million by 2031.
When mutations occur it can lead to a wide range of disease, called laminopathies. One manifestation can be dilated cardiomyopathy, where the muscles of the heart become thin and stretched, making it harder to pump blood to the rest of the body, which can lead to heart failure. There are no therapies for LMNA-related DCM.
The process is followed by computationally guided mutagenesis or evolution of the antibody sequence (hit to lead, or H2L, optimisation) to improve the binding and other properties. Consequently, the lead optimisation or molecular evolution offerings in the space are relatively more common among the start-ups. billion, plus royalties.
during the lead-in pre-treatment period of at least six months. SPK-9001 was licensed by Pfizer from Spark Therapeutics pursuant to a December 2014 agreement, under which Spark was responsible for conducting all phase 1 and 2 studies for the gene therapy. for the 12 months from week 12 to month 15 compared to an ABR of 4.43
A pharmacologist by training, Rawlins was the founding chairman of health technology assessment (HTA) agency NICE , leading the organisation from its inception in 1999 until 2013, and hired Sir Andrew Dillon to become the organisation’s founding chief executive.
GlobalData’s Analyst covering Neurology and Ophthalmology, Thomas Parker, MPharmacol, predicted that Belsomra would lead the market by 2023. billion by 2023, driven by the launch of Merck’s Belsomra and Eisai’s lemborexant (E-2006). million in sales by 2032. percent sales expected in 2032 within the seven major markets.
On 23 August, at a Reuters Newsmakers online forum, Soriot announced his interest in increasing AstraZeneca’s portfolio of bolt-on acquisitions leading up to 2025. In 2014, AstraZeneca acquired Spain’s Almirall , along with the latter’s respiratory franchise, for an initial consideration of $875 million on completion and up to $1.22
This could lead to significant research waste. This will lead to a higher proportion of these medicines becoming licensed, benefitting a larger number of patients. He leads the pre-clinical and clinical medical cannabis research programmes in Europe and is responsible for the cannabis clinic rollout across the continent.
Founded in 2014, the company is headquartered in the San Francisco Bay Area and backed by leading investors in both healthcare and technology. Cala Health’s products are the only FDA-cleared, clinically validated non-invasive devices for the relief of hand tremors so patients with essential tremor can return to the moments that matter.
The global pharmaceutical market passes a significant milestone in 2014: reaching one trillion US dollars in total value. This study indicates that in the wider global context, the UK still matters for launch as one of the lead developed markets which account for the overwhelming majority of the early years of new chemical entity sales.
The pharmaceutical company licensed the gene therapy DURVEQTIX from Spark ® Therapeutics in December 2014. However,] DURVEQTIX has shown the potential to offer long-term bleed protection in a one-time dose, reducing or eliminating bleeds for the appropriate patients with haemophilia B,” de Germay continued.
Conversely, poor analytical characterisation will likely lead to questions from regulators and, without sufficient product and process knowledge, an IND or BLA that is eventually deemed incomplete. Incorrect DNA sequences can also lead to high levels of SVs. While SVs are typically present at less than 0.1
Stakeholder reaction to original EC proposals suggests that changes are considered more favourable for generic/biosimilar manufacturers, given reduced RDP periods could lead to earlier generic/biosimilar entry for both non-orphan and orphan drugs ( see Figure 2 ). By contrast, orphan drugs could become less profitable, more risky investments.
Out of the seven biologics approved to treat moderate to severe CD in adults, only the anti-TNFαs, Remicade (infliximab), and Humira (adalimumab), have been approved for paediatric patients, with Humira receiving the most recent approval in 2014.
Additionally, this could lead to various epidemiological shifts such as certain cancers including colorectal cancer being diagnosed at a more severe stage or increases in the incidence of infectious diseases like HIV.
Our lead candidate MaaT013, a donor-derived, standardised, high-richness, high-diversity MET is currently being evaluated in a Phase III trial (ARES) in Europe and in an Early Access Program in Europe, mostly in acute Graft-versus Host Disease (aGvHD), a severe complication following stem cell transplantation.
Ovarian cancer is the eighth most common cancer worldwide and is the leading cause of death from gynaecological cancers in the US: approximately 20,000 patients are diagnosed annually in the US alone, and 13,000 patients will die from it. Between 35% to 40% of ovarian cancer patients express high levels of FR?
Brandon is not only an SEO industry leader and veteran; he leads Healthcare Success digital marketing team. This is Stuart Gandalf leading another podcast. Super smart leads up all of our SEO, all of our tech stack pretty much anything to do with these kinds of topics. It has not been edited or reviewed for accuracy.
Founded 2014. They’ve worked with leading clients such as Twitter and Mercedes Benz. Founded 2014. CloudHealth Technologies offers a market-leading cloud management platform that helps businesses optimize different cloud environments. Founded 2014. Founded 2014. 51-100 employees. 107 million in funding.
Pharming attempted to extend the use of its C1 esterase inhibitor product Ruconest (conestat alfa) into the prevention setting, having won FDA approval for acute treatment of attacks in 2014, but was knocked back by the regulator. It is administered as an intravenous injection.
On this list, Ukraine was 13th in the Science and Technology category among 124 other countries in 2014, and 14th among 163 countries in 2020. Our data shows that the Ministry of Education and Science of Ukraine are leading local authorship in this area. Figure 2: N umber of Ukraine publications across SDGs. Source: Web of Science.
Microsoft discontinued its mapping application, MapPoint, in late 2014. Map My Customers saves planning and routing time, generates leads, segments accounts, tracks sales cadences, and more! Superior security capabilities to protect access to sensitive business data. It has native CRM integration with Microsoft Dynamics.
Insurance exchanges underwent their largest single-year enrollment growth since their inception in 2014, pushing exchange enrollment to yet another all-time high. This may also lead to gaps in care, reduced drug adherence, increased emergency room visits and a decline in chronic care management. The post The U.S.
We organize all of the trending information in your field so you don't have to. Join 8,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content